Abstract
Altered progranulin levels play a major role in neurodegenerative diseases, like Alzheimer’s dementia (AD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), even in the absence of GRN mutations. Increasing progranulin levels could hereby provide a novel treatment strategy. However, knowledge on progranulin regulation in neurodegenerative diseases remains limited. We here demonstrate that cerebrospinal fluid progranulin levels do not correlate with its serum levels in AD, FTD and ALS, indicating a differential regulation of its central and peripheral levels in neurodegeneration. Blood progranulin levels thus do not reliably predict central nervous progranulin levels and their response to future progranulin-increasing therapeutics.
Keywords: Alzheimer’s dementia, amyotrophic lateral sclerosis, biomarker, case-control study, cerebrospinal fluid, frontotemporal dementia, GRN, progranulin, serum.
Current Alzheimer Research
Title:Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease
Volume: 13 Issue: 6
Author(s): Carlo Wilke, Frank Gillardon, Christian Deuschle, Evelyn Dubois, Markus A. Hobert, Jennifer Müller vom Hagen, Stefanie Krüger, Saskia Biskup, Cornelis Blauwendraat, Michael Hruscha, Stephan A. Kaeser, Peter Heutink, Walter Maetzler and Matthis Synofzik
Affiliation:
Keywords: Alzheimer’s dementia, amyotrophic lateral sclerosis, biomarker, case-control study, cerebrospinal fluid, frontotemporal dementia, GRN, progranulin, serum.
Abstract: Altered progranulin levels play a major role in neurodegenerative diseases, like Alzheimer’s dementia (AD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), even in the absence of GRN mutations. Increasing progranulin levels could hereby provide a novel treatment strategy. However, knowledge on progranulin regulation in neurodegenerative diseases remains limited. We here demonstrate that cerebrospinal fluid progranulin levels do not correlate with its serum levels in AD, FTD and ALS, indicating a differential regulation of its central and peripheral levels in neurodegeneration. Blood progranulin levels thus do not reliably predict central nervous progranulin levels and their response to future progranulin-increasing therapeutics.
Export Options
About this article
Cite this article as:
Wilke Carlo, Gillardon Frank, Deuschle Christian, Dubois Evelyn, Hobert A. Markus, Hagen Müller vom Jennifer, Krüger Stefanie, Biskup Saskia, Blauwendraat Cornelis, Hruscha Michael, Kaeser A. Stephan, Heutink Peter, Maetzler Walter and Synofzik Matthis, Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease, Current Alzheimer Research 2016; 13 (6) . https://dx.doi.org/10.2174/1567205013666160314151247
DOI https://dx.doi.org/10.2174/1567205013666160314151247 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning
Current Neuropharmacology Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study
Current Topics in Medicinal Chemistry Meet Our Regional Editor
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms, Proteinopathies and Therapeutic Strategies in Neurodegenerative Disorders
Current Genomics Application of Contemporary Neuroproteomic Techniques in Unravelling Neurological Disorders
Current Protein & Peptide Science The Function of the Selective Inhibitors of Cycloxygenase 2
Mini-Reviews in Medicinal Chemistry Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?
Current Pharmaceutical Design Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology The Endocannabinoid System and Multiple Sclerosis
Current Pharmaceutical Design A Cross-entropy-based Method for Essential Protein Identification in Yeast Protein-protein Interaction Network
Current Bioinformatics PERK-opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration
Current Alzheimer Research Frontotemporal Lobar Degeneration (FTLD): Review and Update for Clinical Neurologists
Current Alzheimer Research Cell Clocks and Neuronal Networks: Neuron Ticking and Synchronization in Aging and Aging-Related Neurodegenerative Disease
Current Alzheimer Research Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets Targeting the Alpha 7 Nicotinic Acetylcholine Receptor to Reduce Amyloid Accumulation in Alzheimers Disease Pyramidal Neurons
Current Pharmaceutical Design Editorial (Hot Topic: Therapeutic Targets in Neurodegenerative Diseases)
Current Enzyme Inhibition The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia
Current Topics in Medicinal Chemistry Docking-Related Survey on Natural-Product-Based New Monoamine Oxidase Inhibitors and Their Therapeutic Potential
Combinatorial Chemistry & High Throughput Screening Selenium and Clinical Trials: New Therapeutic Evidence for Multiple Diseases
Current Medicinal Chemistry A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets